Delta-8 THC Withdrawal in Mice Did Not Measure Human Withdrawal Incidence
Repeated delta-8 THC produced tolerance and antagonist-precipitated withdrawal signs in mice. The experiment establishes dependence-related potential under the tested conditions, not the percentage of human users who will develop withdrawal.
Acute and repeated exposure were tested
Male and female mice underwent cannabinoid-response tests, repeated delta-8 THC treatment and drug-discrimination procedures. Delta-8 produced delta-9-THC-like cues, although potency differed. Similar qualitative effects do not establish identical dosing or risk for every outcome.
The antagonist made a difference
Withdrawal signs were assessed after rimonabant, a cannabinoid-receptor antagonist, was used to precipitate withdrawal. This method increases the opportunity to observe dependence-related behavior. It differs from stopping a cannabis product and waiting for spontaneous symptoms.
Tolerance was supported by more than one comparison
Repeated delta-8 exposure reduced selected acute responses and produced cross-tolerance to another cannabinoid agonist. The findings support adaptation in the cannabinoid system. They do not imply that tolerance removes all effects or makes increasing the dose harmless.
The human claims remain narrower
Injected animal doses, the antagonist procedure and laboratory endpoints limit direct transfer to retail delta-8 products or human diagnostic criteria. Product impurities and composition were not the same question as the tested compound’s pharmacology. The study challenges an assumption that delta-8 lacks dependence potential; it does not quantify human addiction prevalence, establish a universal potency ratio or identify a safe driving interval.
Related analysis: evaluating cannabis tolerance claims.
Primary research
Vanegas SO; Reck AM; Rodriguez CE; Marusich JA; Yassin O; Sotzing G; Wiley JL; Kinsey SG. Assessment of dependence potential and abuse liability of Δ8-tetrahydrocannabinol in mice. Drug and alcohol dependence (2022). DOI: 10.1016/j.drugalcdep.2022.109640.
